Cardiosen

Cardiosense is a venture-backed healthcare technology company developing wearable sensing and AI-driven platforms for noninvasive cardiovascular disease detection and management. Its flagship product, the CardioTag wireless wearable, captures high-fidelity seismocardiographic physiological signals that are analyzed by deep learning algorithms to determine Pulmonary Capillary Wedge Pressure (PCWP) — a critical heart failure indicator — without invasive procedures. The technology received FDA De Novo classification in 2026 and is the first noninvasive tool capable of pressure-guided heart failure management across care settings, from hospitals to home. Cardiosense was co-founded in 2020 and has raised approximately $30M in funding across multiple rounds.